ArticleMolecular imaging and biology2024
Quantitative and Qualitative Assessment of Urinary Activity of
Article in Molecular imaging and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer
A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy (SPOTLIGHT)
Who cites it
10 citing papers in PubMed.
- An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Trial
- True-PositiveJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- A Pilot Study ofThe Prostate · 2026Article
- Mitigating bladder signal inEJNMMI physics · 2026Article
- Bladder activity of different PSMA PET radioligands and impact of furosemide.American journal of nuclear medicine and molecular imaging · 2026Article
- Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Biochemical failure-free survival ofScientific reports · 2025Article
- Article
- Radiohybrid prostate-specific membrane antigen ligand: new frontier in prostate cancer imaging and therapy.Translational andrology and urology · 2024Article
- Normal-organ distribution of PSMA-targeting PET radiopharmaceuticalAmerican journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of urinary activity on interpretation of PROCEDURES: Newly diagnosed or recurrent prostate cancer patients enrolled in LIGHTHOUSE (NCT04186819) or SPOTLIGHT (NCT04186845), respectively, underwent PET/CT 50-70 min after intravenous administration of 296 MBq
resultsIn total, 712/718 scans were evaluable. Reasons for exclusion were cystectomy, renal failure, or urinary catheter in situ (n = 2 each). The median bladder SUV
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.